These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1450297)

  • 21. Risperidone in the treatment of psychotic depression.
    Goto M; Yoshimura R; Kakihara S; Shinkai K; Yamada Y; Kaji K; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):701-7. PubMed ID: 16580110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. REM sleep enhancement by bupropion in depressed men.
    Nofzinger EA; Reynolds CF; Thase ME; Frank E; Jennings JR; Fasiczka AL; Sullivan LR; Kupfer DJ
    Am J Psychiatry; 1995 Feb; 152(2):274-6. PubMed ID: 7840365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
    Versiani M; Moreno R; Ramakers-van Moorsel CJ; Schutte AJ;
    CNS Drugs; 2005; 19(2):137-46. PubMed ID: 15697327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of low-dose fluoxetine in major depression and panic disorder.
    Louie AK; Lewis TB; Lannon RA
    J Clin Psychiatry; 1993 Nov; 54(11):435-8. PubMed ID: 8270588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness.
    Rabkin JG; Rabkin R; Wagner G
    J Clin Psychiatry; 1994 Mar; 55(3):92-7. PubMed ID: 7915270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression.
    Wang Y; Liu X; Peng D; Wu Y; Su Y; Xu J; Ma X; Li Y; Shi J; Cheng X; Rong H; Fang Y
    Neuropsychiatr Dis Treat; 2021; 17():2441-2449. PubMed ID: 34326642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid.
    Mårtensson B; Nyberg S; Toresson G; Brodin E; Bertilsson L
    Acta Psychiatr Scand; 1989 Jun; 79(6):586-96. PubMed ID: 2475012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bupropion sustained release treatment reduces fatigue in cancer patients.
    Cullum JL; Wojciechowski AE; Pelletier G; Simpson JS
    Can J Psychiatry; 2004 Feb; 49(2):139-44. PubMed ID: 15065748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of patients with the highest plasma catecholamine metabolite levels.
    Bowers MB; Swigar ME; Hoffman FJ; Goicoechea N
    Am J Psychiatry; 1988 Feb; 145(2):246-8. PubMed ID: 3422545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personality disorder comorbidity with major depression and response to fluoxetine treatment.
    Fava M; Bouffides E; Pava JA; McCarthy MK; Steingard RJ; Rosenbaum JF
    Psychother Psychosom; 1994; 62(3-4):160-7. PubMed ID: 7846259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal effect of amitriptyline and fluoxetine treatment on plasma phenylacetic acid concentrations in depression.
    Davis BA; Boulton AA; Yu PH; Durden DA; Keegan DL; Bowen RC; Blackshaw S; D'Arcy C; Remillard AJ; Dayal N
    Biol Psychiatry; 1991 Sep; 30(6):600-8. PubMed ID: 1932407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study.
    Amsterdam JD; Fawcett J; Quitkin FM; Reimherr FW; Rosenbaum JF; Michelson D; Hornig-Rohan M; Beasley CM
    Am J Psychiatry; 1997 Jul; 154(7):963-9. PubMed ID: 9210747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluoxetine and desipramine in major depressive disorder.
    Bowden CL; Schatzberg AF; Rosenbaum A; Contreras SA; Samson JA; Dessain E; Sayler M
    J Clin Psychopharmacol; 1993 Oct; 13(5):305-11. PubMed ID: 8227488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute and subacute effects of ECT on plasma HVA, MHPG, and prolactin.
    Devanand DP; Bowers MB; Hoffman FJ; Sackeim HA
    Biol Psychiatry; 1989 Aug; 26(4):408-12. PubMed ID: 2765601
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease.
    Bowers MB
    J Neuropsychiatry Clin Neurosci; 1996; 8(4):450-2. PubMed ID: 9116484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sociodemographic predictors of response to antidepressant treatment.
    Spillmann M; Borus JS; Davidson KG; Worthington JJ; Tedlow JR; Fava M
    Int J Psychiatry Med; 1997; 27(2):129-36. PubMed ID: 9565719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression.
    Nelson JC; Mazure CM; Bowers MB; Jatlow PI
    Arch Gen Psychiatry; 1991 Apr; 48(4):303-7. PubMed ID: 2009031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome.
    Nierenberg AA; McLean NE; Alpert JE; Worthington JJ; Rosenbaum JF; Fava M
    Am J Psychiatry; 1995 Oct; 152(10):1500-3. PubMed ID: 7573590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma levels of metabolites of catecholamine in nicotine-dependent patients treated with varenicline.
    Umene-Nakano W; Yoshimura R; Yoshii C; Hayashi K; Ikenouchi-Sugita A; Katsuki A; Hori H; Nakamura J
    Nicotine Tob Res; 2012 Apr; 14(4):486-9. PubMed ID: 22006914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of bupropion in tricyclic-resistant or intolerant patients.
    Stern WC; Harto-Truax N; Bauer N
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):148-52. PubMed ID: 6406447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.